journal article·2025-12-08

Aerosolizable Formulations of Porcine Extracellular Matrix with Antibacterial and Immunomodulatory Effects

Maria J. Buendia-Otero, Leonel Velez-Roman, Jesus Jimenez-Osorio, Sahimy Ayus-Martinez, William Meza-Morales, Maribella Domenech, Gregory R. Dion, Donald Freytes, Camilo Mora

Publisher page

Abstract

Controlling bacterial presence and inflammation in the larynx remains a significant challenge, especially in contexts where infection and immune responses can affect tissue health, prompting growing interest in developing bioactive materials that can be delivered locally and noninvasively to modulate microbial load and inflammatory responses. In this study, we developed and characterized aerosolizable formulations derived from decellularized extracellular matrix (dECMx) of porcine vocal fold lamina propria (VFLPx) and thyroid cartilage (Cx). These formulations were evaluated for their antibacterial and immunomodulatory effects. The dECMx formulations exhibited heterogeneous microstructures and aggregate sizes smaller than 5 μm, which is consistent with requirements for aerosol delivery. Antibacterial activity against Staphylococcus aureus was assessed through colony-forming unit (CFU) quantification and bacterial growth kinetics, comparing the liquid and aerosol forms. In liquid form, VFLPx reduced CFU counts by ∼66% and Cx by ∼16%, both showing statistically significant reductions compared to controls. In aerosolized form, both formulations demonstrated comparable antibacterial efficacy, with approximately ∼47% reductions in CFU for VFLPx and Cx. Immunomodulatory potential was evaluated using a THP-1 ascGFP reporter cell line, which was stimulated with LPS to activate NF-κB signaling. Exposure to both dECMx formulations significantly attenuated the LPS-induced GFP fluorescence, indicating a suppression of NF-κB-mediated activation. These in vitro results demonstrate that liquid dECM-derived formulations maintain significant antibacterial activity after processing and aerosolization while also inhibiting inflammatory pathways in human macrophages. This highlights their potential as localized treatments to effectively control bacterial infections without causing inflammation.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Tracheal and airway disorders · Voice and Speech Disorders · Tissue Engineering and Regenerative Medicine

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical Engineering, University of Puerto Rico-Mayaguez, Route 108, Mayaguez, Puerto Rico 00681-9000, United States

Bioengineering Graduate Program

University of Puerto Rico-Mayaguez

Department of Otolaryngology-Head & Neck Surgery

University of Cincinnati College of Medicine

Lampe Joint Department of Biomedical Engineering, North Carolina State University/University of North Carolina at Chapel Hill, 4130 Engineering Building III, Campus Box 7115, Raleigh, North Carolina 27695, United States

Funding

National Institute on Deafness and Other Communication Disorders · Division of Biological Infrastructure · Puerto Rico Science, Technology and Research Trust · Division of Engineering Education and Centers · U.S. Department of Defense · National Institute of General Medical Sciences · Office of Integrative Activities

References (100+)

Show source-provided references
1. Weiss, K. Acute Upper Respiratory Infection . https://www.healthline.com/health/acute-upper-respiratory-infection (accessed 2024-11-18).
2. Tobin, E. H.; Thomas, M.; Bomar, P. A. Upper Respiratory Tract Infection s. https://www.ncbi.nlm.nih.gov/books/NBK532961/ (accessed 2024-11-18).
3. Mosenifar, Z. Upper Respiratory Tract Infection . https://emedicine.medscape.com/article/302460-overview?form=fpf (accessed 2024-11-18).
4. 10.1001/archinte.163.4.48710.1001/archinte.163.4.487 ↗
5. CDC. Respiratory Illnesses: Respiratory Viruses and Young Children . https://www.cdc.gov/respiratory-viruses/risk-factors/young-children.html (accessed 2024-10-10).
6. CDC. Respiratory Virus Hospitalization Surveillance Network (RESP-NET) . https://www.cdc.gov/resp-net/dashboard/index.html (accessed 2024-11-18).
7. Popescu N. · Rev. Chir., Oncol., Radiol., ORL, Oftalmol., Stomatol. · 1980 · 25 · 293
8. 10.1038/s41591-023-02424-210.1038/s41591-023-02424-2 ↗
9. 10.1165/rcmb.2022-0208TR10.1165/rcmb.2022-0208TR ↗
10. 10.1038/nrmicro.2017.1410.1038/nrmicro.2017.14 ↗
11. 10.1183/13993003.02086-201610.1183/13993003.02086-2016 ↗
12. 10.1186/s13054-020-03219-410.1186/s13054-020-03219-4 ↗
13. 10.1016/b0-12-370879-6/00416-610.1016/b0-12-370879-6/00416-6 ↗
14. 2010
15. 10.3390/ijerph1818990510.3390/ijerph18189905 ↗
16. 10.1002/lary.3071810.1002/lary.30718 ↗
17. 10.3390/biom1408090410.3390/biom14080904 ↗
18. 10.1186/s13054-016-1448-510.1186/s13054-016-1448-5 ↗
19. 10.3390/pharmaceutics1601009710.3390/pharmaceutics16010097 ↗
20. 10.1208/s12249-014-0092-010.1208/s12249-014-0092-0 ↗
21. 10.3390/fluids502009110.3390/fluids5020091 ↗
22. 10.1101/2020.05.09.08572010.1101/2020.05.09.085720 ↗
23. 10.4161/mabs.2993810.4161/mabs.29938 ↗
24. 10.1089/10763270275350306310.1089/107632702753503063 ↗
25. 10.1097/01.sla.0000165186.79097.6c10.1097/01.sla.0000165186.79097.6c ↗
26. 10.1002/jbm.b.1006210.1002/jbm.b.10062 ↗
27. 10.1016/j.jss.2010.08.03510.1016/j.jss.2010.08.035 ↗
28. 10.1089/ten.2006.12.294910.1089/ten.2006.12.2949 ↗
29. 10.15761/BEM.100011210.15761/BEM.1000112 ↗
30. 10.1371/journal.pone.017116510.1371/journal.pone.0171165 ↗
31. 10.1111/j.1365-2591.2012.02031.x10.1111/j.1365-2591.2012.02031.x ↗
32. 10.1002/lary.2564010.1002/lary.25640 ↗
33. 10.1016/j.actbio.2019.08.02510.1016/j.actbio.2019.08.025 ↗
34. 10.1002/anbr.20210011910.1002/anbr.202100119 ↗
35. 10.1002/anbr.20220009510.1002/anbr.202200095 ↗
36. 10.1007/s12195-023-00769-910.1007/s12195-023-00769-9 ↗
37. 10.1155/2019/964145610.1155/2019/9641456 ↗
38. 10.3390/pharmaceutics1504127710.3390/pharmaceutics15041277 ↗
39. 10.1002/lary.2976910.1002/lary.29769 ↗
40. 10.1128/iai.61.7.2978-2984.199310.1128/iai.61.7.2978-2984.1993 ↗
41. 10.1016/j.biomaterials.2021.12084810.1016/j.biomaterials.2021.120848 ↗
42. 10.1016/j.yexcr.2015.10.01710.1016/j.yexcr.2015.10.017 ↗
43. 10.1021/acsbiomaterials.9b0183710.1021/acsbiomaterials.9b01837 ↗
44. 10.1016/j.bioadv.2025.21442410.1016/j.bioadv.2025.214424 ↗
45. 10.1002/jbm.b.3393610.1002/jbm.b.33936 ↗
46. 10.3390/ijms2412984110.3390/ijms24129841 ↗
47. 10.1038/s41536-022-00269-w10.1038/s41536-022-00269-w ↗
48. 10.1002/jbm.a.3494110.1002/jbm.a.34941 ↗
49. 10.1073/pnas.090585110610.1073/pnas.0905851106 ↗
50. 10.1088/1748-605X/ac361f10.1088/1748-605X/ac361f ↗
51. 10.1080/15476278.2018.150377110.1080/15476278.2018.1503771 ↗
52. 10.1002/ppsc.20240000410.1002/ppsc.202400004 ↗
53. 10.1089/jamp.2011.091610.1089/jamp.2011.0916 ↗
54. 10.1016/j.biomaterials.2007.12.01410.1016/j.biomaterials.2007.12.014 ↗
55. 10.3390/bioengineering1005060210.3390/bioengineering10050602 ↗
56. 10.1007/s00281-011-0291-710.1007/s00281-011-0291-7 ↗
57. 10.1002/jbm.b.3459210.1002/jbm.b.34592 ↗
58. 10.1128/spectrum.00673-2310.1128/spectrum.00673-23 ↗
59. 10.1111/lam.1285110.1111/lam.12851 ↗
60. 10.3389/fbioe.2022.80529910.3389/fbioe.2022.805299 ↗
61. 10.1016/b978-0-12-397157-9.00003-510.1016/b978-0-12-397157-9.00003-5 ↗
62. 10.3389/fncel.2022.84421110.3389/fncel.2022.844211 ↗
63. 10.22203/eCM.v035a0410.22203/eCM.v035a04 ↗
64. 10.1371/journal.pone.031124210.1371/journal.pone.0311242 ↗
65. 10.1089/ten.tea.2016.053810.1089/ten.tea.2016.0538 ↗
66. 10.1016/j.ymeth.2015.03.00510.1016/j.ymeth.2015.03.005 ↗
67. 10.1002/jbm.b.3485110.1002/jbm.b.34851 ↗
68. 10.1039/D2BM01012G10.1039/D2BM01012G ↗
69. 10.1186/s13000-024-01461-w10.1186/s13000-024-01461-w ↗
70. 10.1101/pdb.prot498610.1101/pdb.prot4986 ↗
71. 10.1016/j.biomaterials.2022.12178610.1016/j.biomaterials.2022.121786 ↗
72. 10.1021/acsami.9b0106610.1021/acsami.9b01066 ↗
73. 10.1520/f3354-1910.1520/f3354-19 ↗
74. 10.1016/j.biomaterials.2011.01.05710.1016/j.biomaterials.2011.01.057 ↗
75. 10.1038/ncomms493510.1038/ncomms4935 ↗
76. 10.1016/j.bioactmat.2023.09.01710.1016/j.bioactmat.2023.09.017 ↗
77. Luo Z. · Am. J. Transl. Res. · 2018 · 11 · 1417
78. 10.1016/j.ijpharm.2021.12076810.1016/j.ijpharm.2021.120768 ↗
79. 10.1146/annurev.iy.13.040195.00042510.1146/annurev.iy.13.040195.000425 ↗
80. 10.1016/j.biomaterials.2016.08.05410.1016/j.biomaterials.2016.08.054 ↗
81. 10.1016/j.jvoice.2014.03.00110.1016/j.jvoice.2014.03.001 ↗
82. 10.34133/bmr.012810.34133/bmr.0128 ↗
83. 10.1016/j.lfs.2018.10.05610.1016/j.lfs.2018.10.056 ↗
84. 10.1016/j.regen.2019.10001810.1016/j.regen.2019.100018 ↗
85. 10.1159/00033523910.1159/000335239 ↗
86. 10.1159/00023258710.1159/000232587 ↗
87. 10.1111/j.1432-1033.2004.04035.x10.1111/j.1432-1033.2004.04035.x ↗
88. 10.1159/00035703210.1159/000357032 ↗
89. 10.1186/s13036-021-00282-510.1186/s13036-021-00282-5 ↗
90. 10.1016/j.actbio.2008.09.01310.1016/j.actbio.2008.09.013 ↗
91. 10.1002/EXP.2023007810.1002/EXP.20230078 ↗
92. 10.1007/s10439-019-02408-910.1007/s10439-019-02408-9 ↗
93. 10.1177/108705710426529110.1177/1087057104265291 ↗
94. 10.2174/15680261280067284410.2174/156802612800672844 ↗
95. 10.1016/j.mtbio.2024.10128010.1016/j.mtbio.2024.101280 ↗
96. 10.1016/j.critrevonc.2003.06.00710.1016/j.critrevonc.2003.06.007 ↗
97. 10.1038/s41598-019-56283-410.1038/s41598-019-56283-4 ↗
98. 10.1016/j.athoracsur.2013.04.02210.1016/j.athoracsur.2013.04.022 ↗
99. 10.1016/j.nurpra.2021.12.00210.1016/j.nurpra.2021.12.002 ↗
100. 10.3389/fimmu.2018.0198810.3389/fimmu.2018.01988 ↗